Kristie L. Kahl

A review of current options for management of SCLC and the challenges of treating this population.

An expert in follicular lymphoma highlights factors to consider when choosing therapy for first relapse and how this impacts later line treatment, as well as molecular testing and MRD.

Sameh Gaballa, MD, discusses patients who relapse after frontline treatment as well as prognostic and predictive factors for relapse.

Mark Socinski, MD, of AdventHealth Cancer Institute discusses his approach to treating small cell lung cancer and reacts to advances in the treatment of extensive-stage disease.

An overview of the prevalence and prognosis of small cell lung cancer.

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.

Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.

A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.

The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.

The FDA’s Oncologic Drugs Advisory Committee voted 7 to 2 in favor of atezolizumab plus nab-paclitaxel maintaining its accelerated approval to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.

The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

The CheckMate-816 trial is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer.

CancerNetwork spoke with Eric Jonasch, MD, about the NCCN’s recommendation and how thee multidisciplinary approach will play a role.

The addition of nivolumab to either chemotherapy or ipilimumab improved overall survival among patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, according to data from the phase 3 CheckMate-648 trial.

Sumanta (Monty) K. Pal, MD, evaluated combination regimes, in particular the use of lenvatinib plus pembrolizumab, and what factors are taken into consideration for deciding on treatment.

The FDA approved the addition of isatuximab to the combination of carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Treatment with gilteritinib, compared with salvage chemotherapy, improved overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to a planned interim analysis of a phase 3 trial.

The FDA approved a revised label for daunorubicin/cytarabine to treat newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 and older.

At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, discussed the recommendations issued for the early detection of metastatic prostate cancer using next-generation imaging.

Christopher Lieu, MD, discusses the standard of care for genomic profiling in early stage CRC.

The phase 3 CheckMate 577 trial is the first to show a checkpoint inhibitor in the adjuvant setting after trimodality therapy demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer.

The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.

One year after surgery, patients aged 70 years or older experienced moderate-to-severe tiredness, poor well-being, and lack of appetite.

The use of next-generation imaging, like PSMA PET, has been shown to be superior compared with conventional imaging and may become a homestay in prostate cancer care in the future.

Independent variables, such as the burden of disease prior to treatment, molecular prognosis, sensitivity to chemotherapy, sensitivity to endocrine therapy, and sensitivity to other treatments could be effective in predicting risk of recurrence in patients with breast cancer.

“Neoadjuvant endocrine therapy trials are feasible with relatively low toxicity,” Kelly K. Hunt, MD, FACS, FSSO, said during the 38th Annual Miami Breast Cancer Conference®.

Allowing for the use of antiemetic prophylaxis and anti-diarrheal medication in the phase 3 KX-ORAX-001 study reduced study drug-related gastrointestinal adverse events.

The addition of neratinib to capecitabine improved progression-free survival and central nervous system outcomes in patients with HER2-positive metastatic breast cancer with central nervous system disease.